Skip to main content

Table 1 Association between clinical-pathological features and treatment received (N = 60)

From: Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis

Characteristic

With GnRH N (%)

Without GnRH N (%)

p value*

Age

   

 Median

64

63

0.79

 Range

24–82

29–76

 

ECOG PS

   

 Median

1

1

0.88

 Range

0–2

0–2

 

Hormone receptor status

   

 Positive

32 (86.5)

19 (82.6)

0.99

 Negative

2 (5.5)

2 (8.7)

 

 Unknown

3 (8)

2 (8.7)

 

Adjuvant systemic therapy

   

 Yes

19 (51)

10 (43.5)

0.60

 No

18 (49)

13 (56.5)

 

Prior therapy for metastatic disease

   

 Yes

9 (24)

7 (30.5)

0.99

 No

28 (76)

16 (69.5)

 

Subsequent lines of CT

   

 Median

1

1

0.72

 Range

1–2

1–2

 

Subsequent lines of HT

   

 Median

1

1

0.85

 Range

1–3

1–3

 

Dominant disease site

   

 Viscera

24 (64.9)

14 (60.8)

 

 Bone

9 (24.3)

8 (34.8)

0.98

 Soft-tissue

4 (10.8)

1 (4.4)

 

Number of disease sites

   

 1

11 (29.7)

10 (43.4)

 

 2

21 (56.7)

9 (39.1)

0.99

  ≥ 3

5 (13.6)

4 (17.5)

 
  1. ECOG PS: Eastern Cooperative Oncology Group Performance Status; CT: chemotherapy; HT: hormone therapy
  2. *Fisher exact test